MGC Pharmaceuticals Limited First patient enrolled in MGC ZAM App (0405T)

TIDMMXC

RNS Number : 0405T

MGC Pharmaceuticals Limited

15 March 2023

MGC Pharmaceuticals Ltd.

First patient enrolled in MGC ZAM App - CannEpil(R) Clinical Trial

15 March 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has enrolled the first patient in the Company's proprietary d ata collection App and machine learning algorithm, ZAM, and will log the data from the commencement of an observational study monitoring the effects of MGC Pharma's epilepsy treatment, CannEpil(R).

The app will record daily metrics from patients, their symptoms, and the impact of their treatment in order to establish a baseline. This will provide both medical practitioners and MGC Pharma with a detailed record of the study and an enhanced understanding of the effect of CannEpil(R) on Refractory Epilepsy patients.

The App will not only provide the patients with reminders on how and when to take medication (per their medical practitioners' advice), but will also measure treatment progress, and have the ability for a qualified doctor to prescribe alternative medication following a consultation.

The trial is supported by the "I am Billy" Foundation, a charity set up to aid parents and families in navigating the challenges of obtaining NHS-funded Medical Cannabis for children.

Roby Zomer, co-founder and Managing Director of MGC Pharmaceuticals, commented : "The enrolment of the first patient in the ZAM App in the UK, enables us to fully record the impact and efficacy of our products undergoing trials. Consolidation of data is of paramount importance in ensuring the safety and efficiency of MGC's proprietary products, and we see the integration of both pharma and tech as a revolution in the clinical trial process.

"We are proud to be supporting the "I am Billy" foundation in this endeavour, and are pleased to be recognised as a leading company in the sector."

Authorised for release by the board of directors, for further information please contact:

 
 MGC Pharmaceuticals Ltd                            MGC Pharmaceuticals Ltd 
  Roby Zomer                                         Arron Canicais & Rowan Harland 
  CEO & Managing Director                            Company Secretary 
  +61 8 6382 3390                                    +61 8 6382 3390 
  info@mgcpharma.co.uk                               info@mgcpharma.co.uk 
 UK Financial and Corporate                         UK PR Advisors 
  Advisor                                            Tavistock 
  SW4 Partners                                       Charles Vivian / Tim Pearson 
  Rupert Fane / Nilesh Patel                         +44 207 920 3150 
  +44 7810 056 104                                   mgcpharma@tavistock.co.uk 
  rupert@sw4partners.com / nilesh@sw4partners.com

About I am Billy

I am Billy is a foundation set up to aid parents and families in navigating the challenges of obtaining NHS-funded Medical Cannabis for children. The foundation provides financial assistance in meeting the cost of cannabis based medical products (CBMPs) prescribed by a medical consultant, in addition to advancing the public understanding of the medical benefits of CBMPs.

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil, and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDGPUGWWUPWUQA

(END) Dow Jones Newswires

March 15, 2023 03:00 ET (07:00 GMT)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Apr 2024 to May 2024